Grundlæggende statistik
| LEI | 35ZN6X1ANPH25YN32Y17 |
| CIK | 933974 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Azenta, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) (Zip Code |
|
| May 26, 2026 |
Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us”, is a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company supports its customers from research and clinical development to commercialization with its sample management and automated storage, as well as genomic se |
|
| May 8, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Azenta, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock Other 2,750,000 $ 24.87 $ 68,392,500.00 0.0001381 $ 9,445.00 Total Offering Amounts: $ 68,392,500.00 $ 9,44 |
|
| May 8, 2026 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2026 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 8, 2026 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such |
|
| May 8, 2026 |
As filed with the Securities and Exchange Commission on May 8, 2026 Registration No. |
|
| May 5, 2026 |
AZENTA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029 •FY’26 total reported revenue from continuing operations to range between approximately $603 to $621 million •FY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% g |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| April 7, 2026 |
Exhibit 10.1 April 6, 2026 William “Trey” E. Martin III Dear Trey: On behalf of Azenta, Inc. (“Azenta” or the “Company”), I am pleased to offer you the position of Senior Vice President, President Multiomics pursuant to the terms and conditions set forth in this letter agreement (this “Agreement”). A summary of the terms and conditions of your employment are as follows: 1. Your anticipated start d |
|
| April 7, 2026 |
FIRST AMENDMENT TO OFFER LETTER Exhibit 10.5 FIRST AMENDMENT TO OFFER LETTER THIS FIRST AMENDMENT TO OFFER LETTER (this “Amendment”) is made effective as of the 6th day of April 2026, by and between Azenta, Inc. (“Azenta” or the “Company”) and Ephraim Starr (the “Employee). Recitals The Company and the Employee entered into an Offer Letter dated March 25, 2025 (the “Offer Letter”). The Company and the Employee now wish to amend |
|
| April 7, 2026 |
FIRST AMENDMENT TO OFFER LETTER Exhibit 10.6 FIRST AMENDMENT TO OFFER LETTER THIS FIRST AMENDMENT TO OFFER LETTER (this “Amendment”) is made effective as of the 6th day of April 2026, by and between Azenta, Inc. (“Azenta” or the “Company”) and Olga Pirogova (the “Employee). Recitals The Company and the Employee entered into an Offer Letter dated June 30, 2023 (the “Offer Letter” or “Agreement”). The Company and the Employee now |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 7, 2026 |
Exhibit 99.1 Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution BURLINGTON, MA – April 7, 2026 – Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta |
|
| April 7, 2026 |
FIRST AMENDMENT TO OFFER LETTER Exhibit 10.4 FIRST AMENDMENT TO OFFER LETTER THIS FIRST AMENDMENT TO OFFER LETTER (this “Amendment”) is made effective as of the 6th day of April 2026, by and between Azenta, Inc. (“Azenta” or the “Company”) and Lawrence Lin (the “Employee). Recitals The Company and the Employee entered into an Offer Letter dated November 8, 2024 (the “Offer Letter”). The Company and the Employee now wish to amend |
|
| April 7, 2026 |
Exhibit 10.3 EXHIBIT A CONSULTING SERVICES AGREEMENT Consultant: Ginger Zhou Address: 2607 Cartington CT Email: [email protected] Phone: 732-208-9908 Azenta, Inc., ("Azenta"), having offices at 200 Summit Drive, 6th Floor, Burlington, MA 01803 U.S.A., and the above-named party ("Consultant") agree that the following terms and conditions shall solely and exclusively govern any and all Servic |
|
| April 7, 2026 |
Exhibit 10.2 THIS IS AN IMPORT ANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. April 6, 2026 VIA EMAIL DELIVERY Ginger Zhou [email protected] zhenzhenzhou0 [email protected] Re: Separation Agreement and Release Dear Ginger: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the "Company"). The purpose of this |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 4, 2026 |
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities Exhibit 99.1 Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities BURLINGTON, MA – March 4, 2026 – Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sa |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction (Commission File (IRS Employer of Incorporat |
|
| March 4, 2026 |
Exhibit 2.1 Share Purchase Agreement relating to the sale and purchase of the entire issued share capital of UK Biocentre Limited Dated March 4, 2026 i Contents 1. Definitions and interpretation 1 2. Sale and purchase 10 3. Consideration 13 4. Locked box 14 5. Completion 15 6. Deferred Consideration 16 [***] 17 Payment 17 Conduct of Business 17 7. Post-Completion Undertakings 18 8. Warranties 18 9 |
|
| February 5, 2026 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 5, 2026 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 5, 2026 |
AZENTA, INC. 2020 EQUITY INCENTIVE PLAN As Amended Through November 2, 2025 Exhibit 10.1 AZENTA, INC. 2020 EQUITY INCENTIVE PLAN As Amended Through November 2, 2025 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Azenta, Inc. 2020 Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in w |
|
| February 4, 2026 |
Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025 BURLINGTON, Mass., February 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company’s announcement in t |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2026 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| December 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| December 29, 2025 |
Exhibit 2.1 Execution Copy DATED 23 December 2025 AZENTA GERMANY GMBH and THELEMA S.À R.L. SALE AND PURCHASE AGREEMENT relating to the entire issued share capital of B MEDICAL SYSTEMS S.À R.L. In accordance with Item 601(a)(5) of Regulation S-K, the schedules to this exhibit, which are all listed in the Index, have been omitted. In accordance with Item 601(a)(6) of Regulation S-K, private informat |
|
| December 29, 2025 |
Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S. Exhibit 99.1 Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L. BURLINGTON, Mass., December 29, 2025 /PRNewswire/ -Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta’s B Medical Systems business to THELEMA S.À R.L., for a purchase price of US$63 million. The tr |
|
| December 19, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential |
|
| December 18, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidenti |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 10, 2025 |
Azenta Authorizes $250 Million Share Repurchase Program Exhibit 99.1 Azenta Authorizes $250 Million Share Repurchase Program BURLINGTON, Mass., December 10, 2025 /PRNewswire/ -Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitaliz |
|
| December 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| December 10, 2025 |
Exhibit 99.2 |
|
| December 4, 2025 |
Title: Insider Trading and Confidentiality of Insider Information Exhibit 19 Title: Insider Trading and Confidentiality of Insider Information Effective Date: August 7, 2025 Revision #: R Prepared by: Ephraim Starr, Senior Vice President and General Counsel Approved by: Lawrence Lin, Executive Vice President, Chief Financial Officer Purpose: To define the Company’s rules on insider trading, to establish guidelines on the confidentiality of insider information, to prevent violations of insider trading laws by Company personnel, and to avoid even the appearance of improper conduct in this regard by Company personnel. |
|
| December 4, 2025 |
AZENTA, INC. 2020 EQUITY INCENTIVE PLAN Stock Unit – Award Notice Exhibit 10.12 AZENTA, INC. 2020 EQUITY INCENTIVE PLAN Stock Unit – Award Notice This award notice sets forth the terms of the award (the “Award”), described below, of restricted Stock Units (the “RSUs”) under the Azenta, Inc. (formerly Brooks Automation, Inc.) 2020 Equity Incentive Plan (as amended, the “Plan”) to the Participant identified below. The Award is subject to the terms of the Plan, whi |
|
| December 4, 2025 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| December 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| December 4, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826, and 333-123242) of Azenta, Inc. of our report dated December 4, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which |
|
| December 4, 2025 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| December 4, 2025 |
AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG Switzerland Azent |
|
| December 2, 2025 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: September 30, 2028 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☑ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transitio |
|
| November 21, 2025 |
Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025 ● Q4’25 reported revenue growth of 6% year over year and 4% on an organic basis ● FY’25 reported revenue growth of 4% and 3% on an organic basis ● FY'25 Adjusted EBITDA margin expansion of 310 basis points versus last year ● FY'26 organic revenue growth expected to be 3% to 5% year over year, wit |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 6, 2025 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| August 6, 2025 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 5, 2025 |
Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance BURLINGTON, Mass., August 5, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, followin |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0‑25434 04‑3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) ( |
|
| May 30, 2025 |
Conflict Minerals Report for the year ended December 31, 2024 Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us” is a leading provider of life sciences solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and multiomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and |
|
| May 16, 2025 |
Severance Agreement and Release, dated May 15, 2025, between Azenta, Inc. and Jason W. Joseph. Exhibit 10.1 May 14, 2025 VIA EMAIL DELIVERY Jason W. Joseph Re: Transition and Separation Agreement and Release Dear Jason: This Transition and Separation Agreement and Release (the “Agreement”) summarizes the terms of your employment transition and separation from Azenta, Inc. (the “Company”) and is entered into as of May 15, 2025. 1. Transition. Effective on May 15, 2025 (the “Transition Date”) |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 9, 2025 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| May 9, 2025 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 7, 2025 |
Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 BURLINGTON, Mass., May 7, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company’s announcement in the first |
|
| April 9, 2025 |
Severance Agreement and Release, dated April 9, 2025, between Azenta, Inc. and David Wang Exhibit 10.1 EXHIBIT A THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. April 9, 2025 VIA EMAIL DELIVERY David Wang Re: Separation Agreement and Release Dear David: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this Agreement is to establish an amicable arr |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| February 10, 2025 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 10, 2025 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 5, 2025 |
Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024 BURLINGTON, Mass., February 5, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company’s announcement in t |
|
| January 30, 2025 |
AZENTA, INC. Revised Financial Information Exhibit 99.1 AZENTA, INC. Revised Financial Information As previously disclosed on November 12, 2024, Azenta, Inc. (the “Company”) announced that it is pursuing a sale of its B Medical Systems segment, a manufacturer and global distributor of medical refrigeration devices based in Luxembourg. This strategic action is intended to simplify the Company’s portfolio and allow management to focus on dri |
|
| January 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the |
|
| December 17, 2024 |
December 17, 2024 Dear Fellow Stockholders, I’m excited to write to you in my first shareholder letter since joining Azenta as CEO earlier this year. |
|
| December 17, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidenti |
|
| December 6, 2024 |
AZTA / Azenta, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us1143401024120624.txt us1143401024120624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) Azenta, Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 114340102 - (CUSIP Number) November 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 27, 2024 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826 and 333-123242) of Azenta, Inc. of our report dated November 26, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which |
|
| November 27, 2024 |
Azenta, Inc. Insider Trading and Confidentiality of Insider Information Policy Exhibit 19 Insider Trading and Confidentiality of Insider Information (effective as of February 1, 2022) Purpose: To define the Company’s rules on insider trading, to establish guidelines on the confidentiality of insider information, to prevent violations of insider trading laws by Company personnel, and to avoid even the appearance of improper conduct in this regard by Company personnel. |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 27, 2024 |
Exhibit 4.02 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Azenta, Inc. (referred to herein as “we”, “our”, “us” or “the Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following description of our capital stock summarizes the material te |
|
| November 27, 2024 |
Exhibit 97 AZENTA, INC CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this poli |
|
| November 27, 2024 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| November 27, 2024 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| November 27, 2024 |
EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG Switzerland Azent |
|
| November 13, 2024 |
AZTA / Azenta, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0090889-3sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) September 30, 2024 (Da |
|
| November 12, 2024 |
Exhibit 10.1 THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. November 12, 2024 VIA EMAIL DELIVERY Herman Cueto Re: Transition and Severance Agreement and Release Dear Herman: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this agreement (“Agreement”) is to |
|
| November 12, 2024 |
Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO ● FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics ● FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basi |
|
| November 12, 2024 |
Offer Letter, dated November 11, 2024, between Azenta, Inc. and Lawrence Lin Exhibit 10.2 November 8, 2024 Mr. Lawrence Lin Dear Lawrence: On behalf of Azenta, it is my pleasure to offer you the position of Executive Vice President and Chief Financial Officer. It is intended that you would join Azenta as Executive Vice President, Finance, and you would assume the role of Chief Financial Officer after the Company’s Annual Report on Form 10-K for the fiscal year ended Septem |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 4, 2024 |
AZTA / Azenta, Inc. / Politan Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 tm2427378d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share |
|
| November 4, 2024 |
Exhibit 99.1 Press Release Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Dir |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 4, 2024 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of November 1, 2024 (the “Effective Date”), is by and among Politan Capital Management LP, a Delaware limited partnership, Politan Capital Management GP LLC, a Delaware limited liability company, Politan Capital NY LLC, a New York limited liability company, and Politan Capital Partners GP LLC, a Delaware lim |
|
| October 31, 2024 |
AZTA / Azenta, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Azenta Inc (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| September 4, 2024 |
Exhibit 99.1 AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., September 4, 2024 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| September 4, 2024 |
Employment Agreement, dated September 3, 2024, by and between the Company and John Marotta. Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of the date that this Agreement is fully executed between Azenta, Inc. (the “Company”) and John Marotta (“Executive”) (collectively, the Company and Executive, are the “Parties”). WHEREAS, the Company wishes to employ Executive and Executive wishes to be employed by the Company pursuant to the |
|
| August 6, 2024 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| August 6, 2024 |
Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024 BURLINGTON, Mass., August 6, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operatio |
|
| August 6, 2024 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| May 30, 2024 |
Conflict Minerals Report for the year ended December 31, 2023 Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us” is a leading provider of life sciences solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and multiomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) ( |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 9, 2024 |
Transition Agreement, dated May 8, 2024, between Azenta, Inc. and Stephen S. Schwartz. EXHIBIT 10.1 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) dated May 8, 2024 is between Azenta, Inc., a Delaware corporation (“Company”) and Stephen S. Schwartz (“Employee”). WHEREAS, Employee currently serves as President and Chief Executive Officer of the Company (the “CEO”); WHEREAS, Employee has announced Employee’s intention to retire as the Company’s CEO; WHEREAS, the Com |
|
| May 9, 2024 |
Exhibit 99.1 Azenta Announces CEO Succession Plan CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass., May 8, 2024 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CE |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 8, 2024 |
Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024 BURLINGTON, Mass., May 8, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2024 2023 2023 Prior Qtr Prior Yr. Revenue from Continuing Op |
|
| March 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 14, 2024 |
Exhibit 99.1 © 2024 Azenta, Inc. All rights reserved Transforming our Platform for Sustained Profitable Growth Investor Day March 14, 2024 Azenta Life Sciences | Proprietary and confidential. Welcome Sara Silverman Head of Investor Relations 2 © 2024 Azenta, Inc. All rights reserved Safe Harbor Statement 3 “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; cer |
|
| February 13, 2024 |
BRKS / Brooks Automation, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0391-azentainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 15)* Name of issuer: Azenta Inc Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 13, 2024 |
BRKS / Brooks Automation, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0086862-10sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2023 (Da |
|
| February 8, 2024 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| February 8, 2024 |
Separation Agreement dated January 2, 2024 between the Company and David C. Gray. Exhibit 10.2 THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. December 11, 2023 VIA EMAIL DELIVERY David C. Gray Re: Severance Agreement and Release Dear Dave: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this Agreement is to establish an amicable arrangem |
|
| February 8, 2024 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 8, 2024 |
Transition Letter Agreement dated December 4, 2023 between the Company and Lindon G. Robertson. Exhibit 10.1 December 4, 2023 VIA EMAIL Lindon G. Robertson Re: Transition Letter Agreement Dear Lindon: This Transition Letter Agreement confirms our recent discussions regarding your retirement plans from Azenta Life Sciences (“Azenta”). We have agreed that your last date of employment will be on February 16, 2024. Effective immediately and until that date, your role will be modified to Advisor |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 7, 2024 |
Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023 BURLINGTON, Mass., February 7, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2023. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue fr |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 1, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 31, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 31, 2024 |
Exhibit 99.1 Notes on Non-GAAP Financial Measures Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, purchase price accounting adjustments, tariff adjustments, restructu |
|
| January 24, 2024 |
BRKS / Brooks Automation, Inc. / BlackRock Inc. Passive Investment us1143401024012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) Azenta, Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 114340102 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 15, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permi |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ր ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2023 or տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 Azenta, Inc. (Exa |
|
| November 21, 2023 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| November 21, 2023 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| November 21, 2023 |
Offer Letter, dated September 21, 2023, between the Company and Herman Cueto. Exhibit 10.06 September 21, 2023 Mr. Herman Cueto 855 Boulevard Westfield, NJ 07090 Dear Herman: I am very happy to extend an offer to become part of Azenta (the “Company”) and our executive team. Our numerous discussions have only solidified my strong impressions that you will provide the strategic leadership necessary to continue Azenta’s growth while enabling our customers to bring impactful br |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 21, 2023 |
EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Abeyatech LLC USA Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG |
|
| November 21, 2023 |
Exhibit 4.02 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of September 30, 2023, Azenta, Inc. (referred to herein as “we”, “our”, “us” or “the Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following description of our capital stock |
|
| November 21, 2023 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826 and 333-123242) of Azenta, Inc. of our report dated November 20, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which |
|
| November 15, 2023 |
BRKS / Brooks Automation, Inc. / Politan Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 tm2330790d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share |
|
| November 13, 2023 |
Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation Exhibit 99.2 Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation ● Nominates Didier Hirsch and Martin Madaus for election to the Board of Directors ● Upon the election of Messrs. Hirsch and Madaus, seven of the Board of Directors’ ten members will have been added since 2018 ● Separately, Azenta today announced strong 2023 fourth quarter and full year fiscal 2023 ear |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 13, 2023 |
Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Fiscal 2023 Results, Ended September 30, 2023 ● Q4’23 reported revenue growth of 25% year over year and 2% on an organic basis ● FY’23 reported revenue growth of 20% and down 1% on an organic basis ● Q4’23 generated positive free cash flow for the second consecutive quarter ● Fiscal 2024 organic revenue growth expected to be 5-8% ● Committin |
|
| November 1, 2023 |
BRKS / Brooks Automation, Inc. / Politan Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 114340102 |
|
| November 1, 2023 |
EX-99.3 2 tm2329437d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected by the Politan Funds since the filing of the Initial 13D. Except as otherwise noted below, all such transactions were purchases or sales of shares of Common Stock effected in the open market, and the table excludes commissions paid in per |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 26, 2023 |
Exhibit 99.1 Azenta Announces CFO Transition Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ – Azenta, Inc. (Nasdaq: AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, w |
|
| September 14, 2023 |
EX-99.1 2 tm2326163d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) |
|
| September 14, 2023 |
Exhibit 99.2 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected in the last sixty days by the Politan Funds. Except as otherwise noted below, all such transactions were purchases or sales of shares of Common Stock effected in the open market, and the table excludes commissions paid in per share prices. Trade Date Expiration Date Buy/Sell No. of |
|
| September 14, 2023 |
BRKS / Brooks Automation, Inc. / Politan Capital Management LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 114340102 (CUSIP Number) Quen |
|
| August 9, 2023 |
AMENDED AND RESTATED BYLAWS OF AZENTA, INC. A DELAWARE CORPORATION Most recently amended as of August 7, 2023 TABLE OF CONTENTS Page ARTICLE I Stockholders1 Section 1.1 Annual Meeting1 Section 1.2 Special Meetings1 Section 1.3 Notice of Meeting1 Section 1.4 Quorum/Adjournments2 Section 1.5 Voting and Proxies2 Section 1.6 Action at Meeting2 Section 1.7 Action Without Meeting3 Section 1.8 Vo |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| August 9, 2023 |
Separation Agreement dated as of August 4, 2023 between the Company and Vandana Sriram THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. August 2, 2023 VIA HAND DELIVERY Vandana Sriram 51 Robinson Road Lexington, MA 02420 Re: Separation Agreement and Release Dear Vandana: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this Agreement is to estab |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 8, 2023 |
Exhibit 99.1 Azenta Reports Results of Third Quarter of Fiscal 2023, Ended June 30, 2023 BURLINGTON, Mass., August 8, 2023 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2023. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operat |
|
| May 31, 2023 |
Conflict Minerals Report for the year ended December 31, 2022 Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us” is a leading provider of life science solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and he |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) ( |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 9, 2023 |
Exhibit 99.1 Azenta Reports Results of Second Quarter of Fiscal 2023 and Announces Business Realignment BURLINGTON, Mass., May 9, 2023 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2023. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2023 2022 2022 Prior Qtr Prior Yr. Revenue fro |
|
| February 14, 2023 |
SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Azenta, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2022 (Date of Event Which R |
|
| February 8, 2023 |
Exhibit 99.1 Azenta Reports First Quarter Results For Fiscal 2023, Ended December 31, 2022 ● Reported Q1’23 Revenue of $178 Million and Growth of 28% Year-Over-Year ● Delivered Organic Growth Excluding COVID of 7% ● Reducing Cost Structure to Deliver Two Points of Margin Enhancement in 2nd Half FY23 BURLINGTON, Mass., February 8, 2023 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported fina |
|
| February 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 8, 2023 |
Exhibit 99.2 1 Azenta Life Sciences | Proprietary and confidential. Conference Call Fir s t Q u a r t e r Fis c al 2 0 2 3 Fin a n cial R e s ults February 8, 2023 2 Azenta Life Sciences | Proprietary and confidential. Safe Harbor Statement Regulation G This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Azenta business and its operational p |
|
| February 2, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 10, 2023 |
BRKS / Brooks Automation, Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0003-azentainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: Azenta Inc. Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur |
|
| January 6, 2023 |
BRKS / Brooks Automation, Inc / BlackRock Inc. Passive Investment us1143401024010523.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Azenta, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 114340102 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 21, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? ? Preliminary Proxy Statement ? ? ? ? ? Confidential, For Use of the Com |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? ? Preliminary Proxy Statement ? ? ? ? ? Confidential, For Use of the Commission Only (as p |
|
| December 15, 2022 |
Table of Contents Exhibit 99.3 ? ? Table of Contents ? ? ? ? Unaudited Pro Forma Condensed Combined Financial Information 1 Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2022 3 Unaudited Pro Forma Condensed Combined Income Statement for the year ended September 30, 2022 5 Note 1. Description of the Transaction 6 Note 2. Basis of Pro Forma Presentation 6 Note 3. Significa |
|
| December 15, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K/A (Amendment No. 1) ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): October 3, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorpora |
|
| December 15, 2022 |
Table of Contents Exhibit 99.2 ? ? B Medical Systems Holding S.A. (in liquidation) Consolidated interim accounts for the six months ended 30 June 2022 ? ? ? ? ? ? ? ? ? ? ? ? Op der Hei, 17 L-9809 Hosingen Luxembourg R.C.S. Luxembourg : B 94593 Share capital: EUR 31,000 Table of Contents Exhibit 99.2 ? ? Contents Page(s) ? ? Consolidated balance sheet as at 30 June 2022 (unaudited) 1 ? ? Consolida |
|
| December 15, 2022 |
Table of Contents Exhibit 99.1 B Medical Systems Holding S.A. (in liquidation) Consolidated annual accounts for the years ended 31 December 2021 and 2020 ? ? ? Op der Hei, 17 L-9809 Hosingen Luxembourg R.C.S. Luxembourg : B 94593 Share capital: EUR 31,000 ? ? ? Table of Contents ? ? ? ? ? Contents Page(s) ? ? ? Report of the Independent Auditors ? 1 ? ? ? Consolidated balance sheet at 31 December |
|
| November 25, 2022 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826, 333-123242 and 333-142873) of Azenta, Inc. of our report dated November 25, 2022, relating to the consolidated financial statements and the effectiveness of internal control over f |
|
| November 25, 2022 |
EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Abeyatech LLC USA Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 25, 2022 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| November 25, 2022 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| November 23, 2022 |
Azenta Announces $500 Million Accelerated Share Repurchase Agreement Exhibit 99.1 Azenta Announces $500 Million Accelerated Share Repurchase Agreement CHELMSFORD, Mass., November 23, 2022 (PR Newswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into an accelerated share repurchase agreement (?ASR?) with JP Morgan Chase Bank, N.A. (the ?Dealer?) to repurchase $500 million of the Company?s common stock. The ASR was entered into pursuant to the |
|
| November 23, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 23, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 23, 2022 |
? Exhibit 10.1 ? ? To: Azenta, Inc. 15 Elizabeth Drive Chelmsford, Massachusetts 01824 ? ? From: JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 ? ? Re: Accelerated Stock Repurchase Transaction(s) ? ? Date: November 23, 2022 ? ? ? This master confirmation (this ?Master Confirmation?), dated as of November 23, 2022, is intended to set forth certain te |
|
| November 14, 2022 |
Exhibit 99.1 ? Azenta Reports Fourth Quarter and Full Year Fiscal 2022 Results, Authorizes $1.5 Billion Share Repurchase Program ? ? Delivered on Expected Q4?22 Revenue of $138 million ? Strong Double-Digit Organic Growth Excluding COVID for Q4 and Full Fiscal Year ? Plan to Repurchase at Least $1 Billion of Common Stock Over the Coming Year, Including $500 Million Accelerated Share Repurchase Pro |
|
| November 14, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 11, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 17, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): October 12, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 7, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): October 3, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 7, 2022 |
? Exhibit 99.1 ? ? ? ? Azenta Announces Completion of B Medical Systems Acquisition ? CHELMSFORD, Mass., October 3, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has closed its previously announced acquisition of B Medical Systems S.? r.l and its subsidiaries (?B Medical?), a market leader in temperature-controlled storage and transportation solutions that enables the del |
|
| August 10, 2022 |
? Exhibit 99.1 ? Azenta Announces Agreement to Acquire B Medical Systems ? Enhances Azenta?s Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., August 8, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.? r.l and its subsidiaries (?B Medical?), a market leader |
|
| August 10, 2022 |
Exhibit 2.1 ? DATED 8 AUGUST 2022 ? ? Certain identified information has been omitted from this exhibit because it is not material and of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. ? B MEDICAL SYSTEMS HOLDING S.A. ? - and - AZENTA LUXEMBOURG S.? R.L. ? - and - ? AZENTA, INC. ? ? SHARE PURCHASE AGREEMENT IN RESPECT OF ? B MEDIC |
|
| August 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): August 8, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): August 9, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2022 |
Exhibit 99.1 Azenta Life Sciences Reports Results of Third Quarter of Fiscal 2022, Ended June 30, 2022 ? CHELMSFORD, Mass., August 9, 2022 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2022. ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Quarter Ended ? ? ? ? ? ? ? Dollars in millions, except per share data ? June 30, ? March 31, ? Jun |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2022 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| August 9, 2022 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| July 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): July 13, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 13, 2022 |
Exhibit 99.1 Azenta Reports Preliminary Results for Third Quarter of Fiscal 2022, Ended June 30, 2022 and Announces Earnings Conference Call and Webcast CHELMSFORD, Mass., July 13, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022. The Company expects revenue of approximately $133 million, an increase of 3% compared |
|
| June 15, 2022 |
Azenta Announces Agreement to Acquire Barkey Holding GmbH Exhibit 99.1 ? Azenta Announces Agreement to Acquire Barkey Holding GmbH ? CHELMSFORD, Mass., June 8, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries (?Barkey?), a leading provider of controlled rate thawing devices to medical, biotech and pharma industries. Barkey is headquartered i |
|
| June 15, 2022 |
Exhibit 2.1 Execution Version ? ? AGREEMENT ON THE SALE AND TRANSFER OF SHARES (Vertrag ?ber den Kauf und die Abtretung von Gesch?ftsanteilen) ? between MR THOMAS BARKEY and SWISSFINITY I BETEILIGUNGS GMBH as Sellers and AZENTA GERMANY GMBH as Buyer ? and MR CHRISTIAN BARKEY ? STRICTLY PRIVATE AND CONFIDENTIAL ? [NOTARIAL FORM REQUIRED] ? ? Execution Version CONTENTS CLAUSE PAGE ? ? ? ? ? ? 1. Int |
|
| June 15, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 7, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 8, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 7, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 8, 2022 |
Press release issued on June 8, 2022 by Azenta, Inc. Exhibit 99.1 ? Azenta Announces Agreement to Acquire Barkey Holding GmbH ? CHELMSFORD, Mass., June 8, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries (?Barkey?), a leading provider of controlled rate thawing devices to medical, biotech and pharma industries. Barkey is headquartered i |
|
| June 8, 2022 |
Exhibit 2.1 Execution Version ? ? AGREEMENT ON THE SALE AND TRANSFER OF SHARES (Vertrag ?ber den Kauf und die Abtretung von Gesch?ftsanteilen) ? between MR THOMAS BARKEY and SWISSFINITY I BETEILIGUNGS GMBH as Sellers and AZENTA GERMANY GMBH as Buyer ? and MR CHRISTIAN BARKEY ? STRICTLY PRIVATE AND CONFIDENTIAL ? [NOTARIAL FORM REQUIRED] ? ? Execution Version CONTENTS CLAUSE PAGE ? ? ? ? ? ? 1. Int |
|
| May 26, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) ? Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) ? (Commission File Number) ? (IRS Employer Identification No.) ? ? 15 Elizabeth Drive, Chelmsford, MA 01824 (Address of Principal Executive Offices |
|
| May 26, 2022 |
Conflict Minerals Report for the year ended December 31, 2021 ? Exhibit 1.01 Introduction Azenta Life Sciences, also referred to as ?Azenta?, ?we?, ?our?, and ?us? is a leading provider of life science solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, acade |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2022 |
? ? SEC FILE NUMBER 000-25434 ? CUSIP NUMBER 114340102 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 9, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 9, 2022 |
Exhibit 99.1 Azenta Life Sciences Reports Preliminary Results of Second Quarter of Fiscal 2022, Ended March 31, 2022 ? Robust customer demand bolstered by operational execution drives strong second quarter results ? CHELMSFORD, Mass., May 9, 2022 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022. ? ? Summary of Prel |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 10, 2022 |
SC 13G/A 1 tm225951d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Azenta, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number |
|
| February 9, 2022 |
BRKS / Brooks Automation, Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Azenta Inc. Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 8, 2022 |
Exhibit 99.1 Azenta Life Sciences Reports Results of First Quarter of Fiscal 2022, Ended December 31, 2021 Continued Double-Digit Growth, Healthy End Markets, and a Strong Balance Sheet CHELMSFORD, Mass., February 8, 2022 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fiscal quarter ended December 31, 2021. ? ? Summary of Results Results of continuing operatio |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): February 8, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 1, 2022 |
Exhibit 2.1 ? FIRST AMENDMENT TO THE EQUITY INTEREST PURCHASE AGREEMENT This FIRST AMENDMENT TO THE EQUITY INTEREST PURCHASE AGREEMENT (this ?Amendment?), dated as of January 31, 2022, is entered into by and between Altar BidCo, Inc., a Delaware corporation (?Purchaser?), and Azenta, Inc. (f/k/a Brooks Automation, Inc.), a Delaware corporation (?Seller?). Capitalized terms used but not defined her |
|
| February 1, 2022 |
BRKS / Brooks Automation, Inc / BlackRock Inc. Passive Investment us1143401024020122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) BROOKS AUTOMATION INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 114340102 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 1, 2022 |
Exhibit 99.1 ? Azenta Life Sciences Completes Sale of Semiconductor Solutions Group Business to Thomas H. Lee Partners CHELMSFORD, Mass., February 1, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has completed the previously announced sale of the company?s Semiconductor Solutions Group business (or ?automation business?) to Thomas H. Lee Partners (?THL?) for $3.0 billion |
|
| February 1, 2022 |
? Exhibit 10.1 STANDARD COMMERCIAL LEASE ARTICLE 1.00 BASIC LEASE TERMS 1.01Parties. This Standard Commercial Lease (this ?Lease?) is entered into as of this February 1, 2022 (the ?Effective Date?) by and between ALTAR BIDCO, INC., a Delaware corporation (?Landlord?), and AZENTA, INC. (f/k/a BROOKS AUTOMATION, INC.), a Delaware corporation (?Tenant?). 1.02Premises. In consideration of the rents, t |
|
| February 1, 2022 |
? Exhibit 10.2 STANDARD COMMERCIAL LEASE ARTICLE 1.00 BASIC LEASE TERMS 1.01Parties. This Standard Commercial Lease (this ?Lease?) is entered into as of this February 1, 2022 (the ?Effective Date?) by and between ALTAR BIDCO, INC., a Delaware corporation (?Landlord?), and AZENTA, INC. (f/k/a BROOKS AUTOMATION, INC.), a Delaware corporation (?Tenant?). ? 1.02Premises. In consideration of the rents, |
|
| February 1, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 28, 2022 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 15, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permi |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? ? Preliminary Proxy Statement ? ? ? ? ? Confidential, For Use of the Commission Only (as p |
|
| December 1, 2021 |
Amended and Restated Bylaws of Azenta, Inc., effective as of December 1, 2021. Exhibit 3.2 ? ? ? ? ? ? ? ? ? ? ? ? AMENDED AND RESTATED BYLAWS OF AZENTA, INC. A DELAWARE CORPORATION ? ? ? Most recently amended as of ? December 1, 2021 ? ? ? TABLE OF CONTENTS ? Page ? ? ARTICLE I. Stockholders 1 ? ? Section 1.1. Annual Meeting 1 ? ? Section 1.2. Special Meetings 1 ? ? Section 1.3. Notice of Meeting 1 ? ? Section 1.4. Quorum 2 ? ? Section 1.5. Voting and Proxies 2 ? ? Section |
|
| December 1, 2021 |
Exhibit 3.1 ? CERTIFICATE OF AMENDMENT ? TO ? CERTIFICATE OF INCORPORATION ? OF ? BROOKS AUTOMATION, INC. ? It is hereby certified that: ? 1.The name of the corporation (hereinafter called the ?Corporation?) is Brooks Automation, Inc. ? 2.The date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was November 14, 1994. Th |
|
| December 1, 2021 |
Exhibit 99.1 Azenta, Inc. (Nasdaq: AZTA) Announces Completion of Corporate Name and Stock Ticker Symbol Change from Brooks Automation, Inc. (Nasdaq: BRKS) Effective at the open of market trading today, the Company will begin trading as Azenta, Inc. (Nasdaq: AZTA) CHELMSFORD, Mass., December 1, 2021 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) (?Azenta? or the ?Company?) announced today that it has |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2021 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| November 24, 2021 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 ? ? CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-23313) and Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826, 333-123242 and 333-142873) of Brooks Automation, Inc. of our report dated November 24, 2021, relating to the consolidated financial statements and |
|
| November 24, 2021 |
Exhibit 10.17 [NAME] BROOKS AUTOMATION, INC. 2020 EQUITY INCENTIVE PLAN Stock Unit ? Award Notice This award notice sets forth the terms of the award (the ?Award?), described below, of restricted Stock Units (the ?RSUs?) under the Brooks Automation, Inc. 2020 Equity Incentive Plan (the ?Plan?) to the Participant identified below. The Award is subject to the terms of the Plan, which are incorporate |
|
| November 24, 2021 |
Letter Agreement, dated October 4, 2021, between the Company and Amy Liao. Exhibit 10.08 ? ? ? Brooks Automation, Inc. 15 Elizabeth Drive Chelmsford, MA 01824 Tel (978) 262-2400 Fax (978) 262-2500 www.brooks.com October 4, 2021 Amy Liao Dear Amy: As a follow up to our discussion, the following terms surrounding your position will be effective as of October 11, 2021. We believe you can continue to provide significant value to our Company given our current business focus a |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 24, 2021 |
EXHIBIT 21.01 ? BROOKS AUTOMATION, INC. SUBSIDIARIES OF THE REGISTRANT ? ? ? Legal Entity Jurisdiction Abeyatech LLC USA Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta Switzerland AG Switzerland Azenta UK Ltd UK Azenta US, Inc. USA BioSpeciman Corporation Canada Biostorage Technologies Asia Pacific Pte Ltd Sing |
|
| November 24, 2021 |
Exhibit 10.21 ? Non-Employee Directors ? [Year] Stock Grant/RSU Election Form ? Name (Last, First, Middle Initial) ? This form allows you to elect between shares of Brooks stock or Restricted Stock Units (?RSUs?) that may be awarded to you during calendar year [Year] under the Brooks Automation, Inc. 2020 Equity Incentive Plan (?Plan?) as compensation for your service as a member of the Board of D |
|
| November 24, 2021 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this annual report on Form 10-K of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| November 24, 2021 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| November 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 18, 2021 |
FinancialOverview–Driving Growth Lindon Robertson, EVP and Chief Financial Officer Exhibit 99.1 FinancialOverview?Driving Growth Lindon Robertson, EVP and Chief Financial Officer ? ? A G E N D A Financial Overview ? Driving Growth Strong performance track record Disciplined capital allocation Outlook: Compelling growth ahead 2 ? 2021 Brooks Automation, Inc. ? Proprietary Information ? ? The Growth Continues ? Building a Powerhouse in Life Sciences FY2019 FY2021 4% 17% Non-GAAP f |
|
| November 18, 2021 |
Exhibit 99.2 Brooks Automation Announces Planned Name and Stock Ticker Symbol Change ? Azenta, Inc. (Nasdaq: AZTA) Set to Begin Trading Effective December 1st CHELMSFORD, Mass., November 16, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) announced at its investor day earlier today that it is changing its name to Azenta, Inc. and will begin trading on Nasdaq under the ticker symbol AZT |
|
| November 10, 2021 |
Exhibit 99.1 Brooks Automation Reports Results of Fourth Quarter of Fiscal 2021, Ended September 30, 2021, and Announces Quarterly Cash Dividend ? Strong Double-Digit Growth Quarter Underscores Robust Demand Environment in Life Sciences ? CHELMSFORD, Mass., November 10, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the fiscal quarter ended Septemb |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2021 |
Brooks Automation Names Frank Casal to its Board of Directors Exhibit 99.1 Brooks Automation Names Frank Casal to its Board of Directors CHELMSFORD, Mass., November 3, 2021 (PR Newswire) ? Brooks Automation, Inc. (Nasdaq: BRKS) today announced that Frank Casal has been elected to its Board of Directors. Mr. Casal most recently served as Vice Chair, Audit for KPMG, LLP, the U.S. member firm of KPMG International (KPMGI). He joins the Brooks Board and Audit Co |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2021 |
? Exhibit 99.1 Brooks Automation Announces Transition and Departure Plans of Dr. Amy Liao ? CHELMSFORD, Mass., October 7, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) announced today that Dr. Amy Liao, President of Life Sciences Services, will be transitioning into the role of strategic advisor to the CEO until the end of this calendar year, at which time she will leave the Company |
|
| September 21, 2021 |
Exhibit 99.2 Brooks Automation Conference Call: Divestiture of Brooks Semiconductor Solutions Group Business September 20, 2021 Exhibit 99.2 ? 2021 Brooks Automation, Inc. ? Proprietary Information Safe Harbor Statement ?Safe Harbor? Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Compa |
|
| September 21, 2021 |
Exhibit 2.1 EQUITY INTEREST PURCHASE AGREEMENT by and between BROOKS AUTOMATION, INC. and ALTAR BIDCO, INC. Dated as of September 20, 2021 ? ? ? ? ? ? ? ? TABLE OF CONTENTS ? ? ? ? ? Page ARTICLE I DEFINITIONS AND DOCUMENTARY CONVENTIONS 2 1.1 Definitions 2 1.2 Exhibits and Schedules; Interpretation 22 ARTICLE II PURCHASE AND SALE OF EQUITY INTERESTS 22 2.1 Sale and Purchase of Equity Interests 22 |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 21, 2021 |
? Exhibit 99.1 BROOKS AUTOMATION ANNOUNCES AGREEMENT TO SELL ITS SEMICONDUCTOR SOLUTIONS GROUP BUSINESS TO THOMAS H. LEE PARTNERS ? Thomas H. Lee Partners to acquire the automation business for $3 billion in cash Transaction proceeds will be used to accelerate growth of life sciences business ? CHELMSFORD, Mass., September 20, 2021 (PRNEWSWIRE) - Brooks Automation, Inc. (Nasdaq: BRKS) today announ |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
